Log In
Or create an account -> 
Imperial Library
  • Home
  • About
  • News
  • Upload
  • Forum
  • Help
  • Login/SignUp

Index
Cover  Title Page Copyright Dedication Contents  Acknowledgments Introduction Chapter One: Historical Themes and Developments at FDA Over the Past Fifty Years Part One: FDA in a Changing World
Introduction Chapter Two: A Global and Innovative Regulatory Environment for the U.S. FDA Chapter Three: FDA and the Rise of the Empowered Patient Chapter Four: After the FDA: A Twentieth-Century Agency in a Postmodern World Chapter Five: The Future of Prospective Medicine Under the Food and Drug Administration Amendments Act of 2007
Part Two: Preserving Public Trust and Demanding Accountability
Introduction Chapter Six: Global Trends Toward Transparency in Participant-Level Clinical Trials Data Chapter Seven: Conflicts of Interest in FDA Advisory Committees: The Paradox of Multiple Financial Ties Chapter Eight: The Crime of Being in Charge: Executive Culpability and Collateral Consequences Chapter Nine: Recalibrating Enforcement in the Biomedical Industry: Deterrence and the Primacy of Protecting the Public Health
Part Three: Protecting the Public Within Constitutional Limits
Introduction Chapter Ten: Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection Chapter Eleven: The FDCA as the Test for Truth of Promotional Claims Chapter Twelve: Why FDA’s Ban on Off-Label Promotion Violates the First Amendment: A Study in the Values of Commercial Speech Protection
Part Four: Timing Is Everything: Balancing Access and Uncertainty
Introduction Chapter Thirteen: Speed Versus Safety in Drug Development Chapter Fourteen: Overcoming “Premarket Syndrome”: Promoting Better Postmarket Surveillance in an Evolving Drug-Development Context Chapter Fifteen: FDA’s Public Health Imperative: An Increased Role for Active Postmarket Analysis
Part Five: Old and New Issues in Drug Regulation
Introduction Chapter Sixteen: The Drug Efficacy Study and Its Manifold Legacies Chapter Seventeen: Drug Safety Communication: The Evolving Environment Chapter Eighteen: Innovation Policy Failures in the Manufacturing of Drugs
Part Six: Regulatory Exclusivities and the Regulation of Generic Drugs and Biosimilars
Introduction Chapter Nineteen: From “Recycled Molecule” to Orphan Drug: Lessons from Makena Chapter Twenty: FDA, Negotiated Rulemaking, and Generics: A Proposal Chapter Twenty-One: The “Follow-On” Challenge: Statutory Exclusivities and Patent Dances Chapter Twenty-Two: FDA Regulation of Biosimilars
Part Seven: New Wine in Old Bottles: FDA’s Role in Regulating New Technologies
Introduction Chapter Twenty-Three: Analog Agency in a Digital World Chapter Twenty-Four: Twenty-First-Century Technology with Twentieth-Century Baggage: FDA Regulation of Regenerative Medicine Chapter Twenty-Five: Device-ive Maneuvers: FDA’s Risk Assessment of Bifurcated Direct-to-Consumer Genetic Testing Chapter Twenty-Six: A New Regulatory Function for E-Prescriptions: Linking FDA to Physicians and Patient Records Chapter Twenty-Seven: Race and the FDA
Contributors Index
  • ← Prev
  • Back
  • Next →
  • ← Prev
  • Back
  • Next →

Chief Librarian: Las Zenow <zenow@riseup.net>
Fork the source code from gitlab
.

This is a mirror of the Tor onion service:
http://kx5thpx2olielkihfyo4jgjqfb7zx7wxr3sd4xzt26ochei4m6f7tayd.onion